Refractory T-Cell Prolymphocytic Leukemia: Clinical Trials

1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Recruiting 1, Terminated 1
Phase 2	1	Recruiting 1

Follow Refractory T-Cell Prolymphocytic Leukemia: new trials by email Literature Review of Refractory T-Cell Prolymphocytic Leukemia trials Research Report on Refractory T-Cell Prolymphocytic Leukemia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia Ruxolitinib, Cladribine, Venetoclax - T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia	Phase 1 / Phase 2	Recruiting	M.D. Anderson Cancer Center	36	2026-04-28	2026-08-12
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia	Phase 1	Terminated	M.D. Anderson Cancer Center	19	2021-04-09	2024-12-12

Narrower conditions

Leukemia, Prolymphocytic, T-Cell (2)  ·  Blast Crisis (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Broader conditions

Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Leukemia (2)  ·  Leukemia, Lymphoid (2)  ·  Leukemia, Prolymphocytic (2)  ·  Leukemia, T-Cell (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Bone Marrow Diseases (1)  ·  Carcinogenesis (1)  ·  Cell Transformation, Neoplastic (1)

Interventions

Cladribine (1)  ·  Cytarabine (1)  ·  fludarabine (1)  ·  ruxolitinib (1)  ·  venetoclax (1)

Sponsors

M.D. Anderson Cancer Center (2)

Countries

United States (2)

Top investigators

Tapan Kadia, MD (1)  ·  Tapan M Kadia (1)